| Literature DB >> 33682829 |
Stefano Mancini1, Silvia Alboni2, Giorgio Mattei3, Giulia Rioli4, Paola Sena5, Mattia Marchi6, Andrea Sacchetti7, Valentina Boarino8, Luca Roncucci9, Gian Maria Galeazzi10, Silvia Ferrari11.
Abstract
Background and aim of the work Colorectal mucosal precancerous lesions, metabolic syndrome (MetS) and psychiatric disorders may share a common low-grade local and systemic inflammation. Aim is to report on preliminary data concerning a research adopting a psycho-neuro-endocrine-immune (PNEI) approach to study outpatients undergoing colonoscopy. Methods A sample of patients undergoing colonoscopy was cross-sectionally investigated. Data on colorectal adenomas, MetS, early atherosclerosis, anxious-depressive symptoms, personality traits, and inflammatory markers were statistically analyzed. Results Sixty-two patients were recruited (female 50%, mean age: 60.8±9.4 years). The prevalence of adenomas and MetS was respectively of 45.2% and 41.9%. Anxiety and depressive symptoms were detected in 16 (32.7%) and 9 (18.4%) subjects, respectively. The presence of adenomas positively correlated with male sex (p=0.01), age (p<0.01), IL-6 (p=0.03), hsCRP (p=0.04), and MetS (p=0.03); it was also associated with hsCRP concentration (aOR=3.81, p=0.03). Conclusions Proinflammatory atherogenic status, psychological traits, increased mucosal inflammation, and metabolic parameters may share a common a pathogenic mechanism, worth studying.Entities:
Mesh:
Year: 2020 PMID: 33682829 PMCID: PMC7975933 DOI: 10.23750/abm.v92i1.10197
Source DB: PubMed Journal: Acta Biomed ISSN: 0392-4203
General features of the sample (dichotomous variables).
| Sex M/F | 31/31 | 50/50 | 0 | Presence of adenomas | 19/9(67.9/32.1) |
| Smoke Y/N | 22/40 | 35.5/64.5 | 0 | MetS negative | 16/20 (44.4/55.6) |
| Alcohol Y/N | 42/20 | 67.7/32.3 | 0 | ||
| Sedentary Y/N | 25/37 | 40.3/59.7 | 0 | ||
| Adenoma Y/N | 28/34 | 45.2/54.8 | 0 | Absence of adenomas | 13/22(39.4/71.0) |
| MetS Y/N | 26/36 | 41.9/58.1 | 0 | MetS positive | 15/11(57.7/42.3) |
| Antidepressants Y/N | 3/59 | 4.8/95.2 | 0 | ||
| Anxiolytics Y/N | 4/58 | 6.5/93.5 | 0 | ||
| Statins Y/N | 15/47 | 24.2/75.8 | 0 | ||
| HADS-A pos/neg | 16/33 | 32.7/67.3 | 13 | ||
| HADS-D pos/neg | 9/40 | 18.4/81.6 | 13 | ||
| HADS-AD pos/neg | 4/45 | 8.2/91.8 | 13 | ||
| IMSA pos/neg | 0/28 | 0/100 | 34 |
List of abbreviations: HADS, Hospital Anxiety and Depression Scale; A, anxiety; D, depression; IMSA, InterMed Self-Assessment
Figure 1.Venn Diagram. Prevalence of adenoma, Metabolic Syndrome, symptoms of anxiety and symptoms of depression, and their comorbidity, among 49 patients of the sample. Abbreviation: MetS=Metabolic Syndrome.
General features of the sample (continuous variables).
| Age in years | 62 | 0 | 60.8 | 9.4 | 82 | 44 |
| BMI Kg(m-2) | 62 | 0 | 27.3 | 4.6 | 38.1 | 18.8 |
| w/h ratio | 62 | 0 | 0.9 | 0.1 | 1.2 | 0.8 |
| SBP mmHg | 62 | 0 | 146.0 | 18.2 | 180 | 110 |
| DBP mmHg | 62 | 0 | 83.2 | 10.3 | 105 | 60 |
| Glyc mg/dl | 62 | 0 | 94.1 | 18.3 | 194 | 64 |
| Chol tot mg/dl | 62 | 0 | 196.2 | 19.2 | 241 | 156 |
| HDL mg/dl | 61 | 1 | 49.9 | 10.8 | 77 | 32 |
| LDL mg/dl | 61 | 1 | 119.9 | 16.7 | 154 | 84 |
| VLDL mg/dl | 62 | 0 | 26.6 | 9.1 | 44 | 11 |
| TRGL mg/dl | 62 | 0 | 132.7 | 45.3 | 220 | 57 |
| RS-qIMT | 57 | 5 | 817.8 | 286.4 | 1500 | 434 |
| LS-qIMT | 57 | 5 | 841.2 | 305.0 | 2000 | 503 |
| FMD basal-1 min % | 56 | 6 | 9.6 | 5.6 | 21.1 | 0.0 |
| FMD basal-3 min % | 56 | 6 | 8.6 | 5.9 | 20 | -7.3 |
| FMD 1 min -3 min % | 56 | 6 | -1.3 | 6.2 | 15.5 | -22.5 |
| HADS-A | 49 | 13 | 5.7 | 3.9 | 15 | 0 |
| HADS-D | 49 | 13 | 4.4 | 3.1 | 11 | 0 |
| TCI NS | 43 | 19 | 22.0 | 3.8 | 29 | 15 |
| TCI HA | 43 | 19 | 18.4 | 2.9 | 24 | 10 |
| TCI RD | 43 | 19 | 11.1 | 2.7 | 18 | 6 |
| TCI P | 43 | 19 | 5.4 | 1.6 | 8 | 3 |
| TCI SD | 43 | 19 | 26.4 | 3.9 | 34 | 18 |
| TCI C | 43 | 19 | 21.9 | 4.6 | 31 | 12 |
| TCI ST | 43 | 19 | 20.4 | 3.5 | 28 | 12 |
| SF36 PCS | 49 | 13 | 47.5 | 7.9 | 58.8 | 26.1 |
| SF36 MCS | 49 | 13 | 51.3 | 8.8 | 66.1 | 22.8 |
| SF36 CS | 49 | 13 | 2.8 | 0.9 | 1 | 4 |
| IMSA | 28 | 34 | 7.8 | 4.2 | 3 | 18 |
| hs-CRP (mg/L) | 62 | 0 | 0.6 | 0.4 | 2.1 | 0.2 |
| IL-6 (pg/ml) | 49 | 13 | 0.8 | 0.8 | 5.0 | 0.2 |
| IL-1 (pg/ml) | 18 | 44 | 6.0 | 9.3 | 41.7 | 0.8 |
| MPO mean | 62 | 0 | 60.9 | 8.9 | 80.7 | 37.3 |
| CIRS | 62 | 0 | 0.2 | 0.1 | 0.5 | 0 |
Variables included in the stepwise logistic regression (observations: 37; pseudo-R squared: 0.32).
| Diagnosis of MetS | 0.13 | 0.16 | 0.01; 2.17 |
| Cholesterol levels | 1.06 | 0.05 | 9.99; 1.13 |
| IMT (left) | 1.00 | 0.10 | 0.99; 1.01 |
| CIRS-SI | 0.90 | 0.92 | 0.12; 6.92 |
| HADS-D | 0.97 | 0.87 | 0.67; 1.41 |
| SF36- MCS | 1.05 | 0.48 | 0.92; 1.20 |
| hsCRP | 6.96 | 0.15 | 0.50; 96.53 |
| IL6pgml1 | 1.30 | 0.88 | 0.05; 35.68 |